Loading clinical trials...
Loading clinical trials...
A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
Conditions
Interventions
Zoledronic acid
Locations
10
Australia
Novartis Investigative Site
Westmead, New South Wales, Australia
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Ottawa, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Budapest, Hungary
Start Date
October 25, 2010
Primary Completion Date
February 27, 2019
Completion Date
February 27, 2019
Last Updated
September 20, 2019
NCT06558188
NCT06449742
NCT07474571
NCT06541548
NCT07254429
NCT07412782
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions